Third patient dies in Chinese trial of RiboX Therapeutics' experimental genetic therapy

A patient with an autoimmune disease died after receiving an experimental genetic medicine from RiboX Therapeutics, a Shanghai‑based biotech startup.

The death marks the third fatality reported in the company's ongoing trials, which have been described as popular but opaque.

RiboX had recently received regulatory clearance to begin these studies, but the recent fatalities raise concerns about safety and trial transparency.